E. Patchen Dellinger

Dr. E. Patchen Dellinger

orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2007 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
EGEllie J. C. Goldstein
Ellie J. C. Goldstein
DADaniel A. Anaya
Daniel A. Anaya
E. Patchen DellingerE. Patchen Dellinger
E. Patchen Dellinger
Necrotizing soft-tissue infections (NSTIs) are highly lethal. They are frequent enough that general and specialty physicians will likely have to be i

1 May 2007 in Annals of Surgery
Verified
Journal Article
Closed access
E. Patchen DellingerE. Patchen Dellinger
E. Patchen Dellinger
JTJose M. Tellado
Jose M. Tellado
NSNorberto E. Soto
Norberto E. Soto
SAStanley W. Ashley
Stanley W. Ashley
PBPhilip S. Barie
Philip S. Barie
SUStefan Utzolino
Stefan Utzolino
In patients with severe, necrotizing pancreatitis, it is common to administer early, broad-spectrum antibiotics, often a carbapenem, in the hope of reducing the incidence of pancreatic and peripancreatic infections, although the benefits of doing so have not been proved. A multicenter, prospective, double-blind, placebo-controlled randomized study set in 32 centers within North America and Europe. One hundred patients with clinically severe, confirmed necrotizing pancreatitis: 50 received meropenem and 50 received placebo. Meropenem (1 g intravenously every 8 hours) or placebo within 5 days of the onset of symptoms for 7 to 21 days. Primary endpoint: development of pancreatic or peripancreatic infection within 42 days following randomization. Other endpoints: time between onset of pancreatitis and the development of pancreatic or peripancreatic infection; all-cause mortality; requirement for surgical intervention; development of nonpancreatic infections within 42 days following randomization. Pancreatic or peripancreatic infections developed in 18% (9 of 50) of patients in the meropenem group compared with 12% (6 of 50) in the placebo group (P = 0.401). Overall mortality rate was 20% (10 of 50) in the meropenem group and 18% (9 of 50) in the placebo group (P = 0.799). Surgical intervention was required in 26% (13 of 50) and 20% (10 of 50) of the meropenem and placebo groups, respectively (P = 0.476). This study demonstrated no statistically significant difference between the treatment groups for pancreatic or peripancreatic infection, mortality, or requirement for surgical intervention, and did not support early prophylactic antimicrobial use in patients with severe acute necrotizing pancreatitis.

1 July 2005 in The American Journal of Surgery
Verified
Journal Article
Closed access
E. Patchen DellingerE. Patchen Dellinger
E. Patchen Dellinger
SHSusan M. Hausmann
Susan M. Hausmann
DBDale W. Bratzler
Dale W. Bratzler
RJRosa M. Johnson
Rosa M. Johnson
DDDonna M. Daniel
Donna M. Daniel
JSJonathan R. Sugarman
Jonathan R. Sugarman

1 May 2015 in Journal of Infection and Public Health
Verified
Journal Article
Closed access
APAnne E. Pugel
Anne E. Pugel
VSVlad V. Simianu
Vlad V. Simianu
DFDavid R. Flum
David R. Flum
E. Patchen DellingerE. Patchen Dellinger
E. Patchen Dellinger

1 October 2017 in JAMA Surgery
Verified
Journal Article
Open access
PDF file
E. Patchen DellingerE. Patchen Dellinger
E. Patchen Dellinger
CPCarlos A. Pellegrini
Carlos A. Pellegrini
TGThomas H. Gallagher
Thomas H. Gallagher
The American Medical Association (AMA) Council on Medical Education reports that in 1975 there were 50 993 practicing physicians 65 years or older, but by 2013, this had risen to 241 641 physicians, a 374% increase. Twenty-three percent of practicing physicians were 65 years or older in 2015.1 Historically, the issue of the aging physician has bedeviled the profession. The literature described once-prominent physicians who practiced long after they became dangerous in old age.2- 6 Physicians wondered how to respond to older colleagues whose judgment and skills were declining. Little was known about the relationship between physicians’ age and performance, hampering policy development. Proposals contemplating a mandatory retirement age for physicians generated howls of protest and threats of age-discrimination lawsuits. The end result was tepid calls for professionalism and reporting oneself or colleagues with declining skills, despite evidence that physicians avoid such behavior.2,7,8

1 January 2004 in Critical Care
Verified
Journal Article
Open access
E. Patchen DellingerE. Patchen Dellinger
E. Patchen Dellinger
DADaniel A Anaya
Daniel A Anaya
Blood transfusions remain common practice in the critical care and surgical settings. Transfusions carry significant risks, including risks for transmission of infectious agents and immune suppression. Transmission of bacterial infections, although rare, is the most common adverse event with transfusion. The risk for transmission of viral infections has decreased over time, clearly because tests are becoming more sensitive in detecting certain viral infections such as hepatitis B, hepatitis C, and HIV. Several immunomodulatory effects are thought to be related to transfusions, and these can result in cancer recurrence, mortality, and postoperative infections. Numerous studies have been performed to examine the role of leukoreduction in decreasing these transfusion-related complications but results remain contradictory. We review the infectious risks associated with blood transfusion and the most recent data on its immunologic effects, specifically on cancer recurrence, mortality, and postoperative infections in surgical patients. We also review the use of leukoreduction in blood transfusion and its role in preventing transfusion-transmitted infections and immunomodulatory complications.